Jul 07

Stanford Packard researchers identify T cell that asthma burden in mice.

Stanford Packard researchers identify T cell that asthma burden in mice, for the second time in two years, scientists at the Stanford University School of Medicine, a new type of regulatory T cells, the asthma and airway inflammation in mice found reduced strengthen the theory that a lack of such cells is a major cause of respiratory failure and allergies.

Physicians and therapists can improve these results on current rehabilitation protocols.Download PDF file of the studyAbout the Journal of Rehabilitation Research and DevelopmentJRRD is a leading journal in the field of rehabilitation medicine and technology for more than 40 years. A peer-reviewed, scientifically indexed journal publishes original research papers, review articles, clinical and technical comments from U.S. And international researchers on all rehabilitation research disciplines.About Peripheral T Lymphoma – a biologically diverse PTCL group of hematologic malignancies that values accounts for about 10 to 15 per cent of non-Hodgkin lymphoma and NHL, cases in the U.S. The American Cancer Society that 66,000 new cases of NHL been diagnosed in the U.S. In 2008. The Company estimates the present annual the prevalence of PTCL in the U.S., about 9,500 patients. No medicinal products are moment in the treatment of in the treatment of either first-line and relapsed or refractory low PTCL.

Food and Drug for the use of pralatrexate for treating patients with relapsed or refractory peripheral T lymphoma . The company priority review priority review of the application if it will FDA grants six months from receiving the application to take action of the request. PTCL a biological diverse group of of hematologic malignancies which. Typical have a worse prognosis than others types of lymphomas and are less in traditional chemotherapy There are no agent by FDA in the treatment of patients with PTCL authorized. ‘The NDA on the encouraging efficacy and safety results data we reported earlier in this year having pralatrexate to patients with relapsed or refractory PTCL is based,’said Paul L.